Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.
Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.
A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.
Arvinas announced an ASH poster on preliminary Phase 1 findings for oral BCL6 degrader ARV-393, also called zaloblideg, in relapsed or refractory non-Hodgkin lymphoma. The December 14 presentation will cover safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in T-cell lymphomas. The announcement itself does not provide numerical response results.
Nurix said Sanofi will stop the first-in-human Phase 1 trial of oral STAT6 degrader SAR448272 and end the program. Nurix no longer expects future milestone payments or royalties from this asset, while other licensed programs remain eligible for such payments. The November 3 announcement did not disclose the reason for discontinuation.
PAQ Therapeutics plans to present the first clinical findings for selective KRAS G12D degrader PT0253 at ENA 2026 in Barcelona on November 20. The oral presentation will draw on an ongoing Phase 1 study in advanced solid tumors; a separate poster covers preclinical work. The announcement did not disclose quantitative efficacy results.
Arvinas said it will prioritize a Phase 1b study of its LRRK2 degrader ARV-102 in progressive supranuclear palsy in the European Union and United Kingdom. Trial applications and regulatory authorization remain pending. The company continues discussions with US and Japanese regulators, while the US investigational new drug application remains on hold.
C4 Therapeutics described a DNA-encoded library that incorporates its cereblon-binding ligand collection for target-first molecular glue discovery. The company reported known and novel VAV1 degrader hits as platform validation, while stating that it would not advance VAV1 without a partner. This is a discovery-platform update, not the clinical entry of a new drug candidate.
Kymera reported sustained IRF5 degradation and downstream biomarker changes in its Phase 1 healthy-volunteer study of KT-579, with no serious or severe adverse events observed. A Phase 1b lupus study, LUMORA, is planned for early 2027. These findings support human proof of mechanism, but healthy-volunteer data do not establish clinical benefit in patients.
Monte Rosa announced that Novartis initiated a second Phase 2 study of the VAV1 molecular glue degrader MRT-6160, also called DDY391, in active moderate to severe psoriatic arthritis. The randomized, double-blind, placebo-controlled trial will assess efficacy, safety, tolerability, and dose response. The first patient visit triggers a $37.5 million milestone payment.
Researchers developed BET-targeting PROTACs that recruit the tissue-restricted scaffolding protein MAGEA11 rather than relying on widely expressed ligases. Lead compound 105B degraded BET proteins in two cancer cell lines but not in HEK293T cells. Mechanistic experiments implicated MAGEA11 and HUWE1. The authors emphasized that further optimization is needed to produce selective cytotoxicity.
Insilico Medicine nominated ISM9546 as a preclinical candidate for autoimmune diseases, including inflammatory bowel disease and rheumatoid arthritis. The company described an orally available, peripherally restricted VAV1 molecular glue degrader, reporting cellular degradation activity and anti-inflammatory effects in disease models. Its limited brain exposure is a design feature; human safety and efficacy have not been established.
Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.
